Magnetic resonance imaging (MRI)-targeted, 3D transrectal ultrasound (TRUS)-guided "fusion" prostate biopsy aims to reduce the 21-47% false negative rate of clinical 2D TRUS-guided sextant biopsy, but still has a substantial false negative rate. This could be improved via biopsy needle target optimization, accounting for uncertainties due to guidance system errors, image registration errors, and irregular tumor shapes. As an initial step toward the broader goal of optimized prostate biopsy targeting, in this study we elucidated the impact of biopsy needle delivery error on the probability of obtaining a tumor sample, and on the core involvement. These are both important parameters to patient risk stratification and the decision for active surveillance vs. definitive therapy. We addressed these questions for cancer of all grades, and separately for high grade (≥ Gleason 4+3) cancer. We used expert-contoured gold-standard prostatectomy histology to simulate targeted biopsies using an isotropic Gaussian needle delivery error from 1 to 6 mm, and investigated the amount of cancer obtained in each biopsy core as determined by histology. Needle delivery error resulted in variability in core involvement that could influence treatment decisions; the presence or absence of cancer in 1/3 or more of each needle core can be attributed to a needle delivery error of 4 mm. However, our data showed that by making multiple biopsy attempts at selected tumor foci, we may increase the probability of correctly characterizing the extent and grade of the cancer.
DESCRIPTION OF PURPOSE2D transrectal ultrasound (TRUS)-guided biopsy is the clinical standard for prostate cancer (PCa) diagnosis. As PCa is often not detectable on ultrasound, a systematic template containing 6-12 cores is used for needle guidance. However, this has a false negative rate of 21-47% and many patients require repeat biopsies 1,2 . Additionally, this biopsy method has been shown to under-and overestimate the true Gleason score of a patient's cancer 3 . While augmented approaches for systematic template biopsy have been proposed 4 , it has also been shown that multiparametric MRI (mpMRI) is effective for PCa detection and localization 5 , which allows for a targeted biopsy approach. To avoid the cost and challenging logistics of in-bore MRI-guided biopsy and enable widespread implementation, 3D TRUS-guided "fusion" biopsy systems have been developed that allow for magnetic resonance imaging targeting via image registration. One specific fusion biopsy system 6 has shown improved positive core rates of 30.4% (compared to 7.1% for 2D TRUS) and 42.3% (compared to 25.6% for 2D TRUS) for moderate and high suspicion lesions, respectively 7 .Although fusion biopsy increased positive core rates, there is significant room for further improvement. Our previous work showed that an improved positive core rate could be obtained by optimizing the number of samples taken from each target, according to lesion size and shape, and the error of the biopsy system 8 . We showed that if o...